Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956240 | 0.91 | PIK3CA (0.46) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9957558 | 0.91 | RBP4 (0.44) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955711 | 0.89 | PIK3CA (0.49) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955645 | 0.89 | RXFP1 (0.46) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955122 | 0.87 | RXFP1 (0.42) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955836 | 0.86 | PIK3CA (0.46) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955830 | 0.86 | PIK3CG (0.48) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9955664 | 0.86 | PIK3CA (0.44) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9956862 | 0.86 | RXFP1 (0.47) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 | |
| SCHEMBL9956646 | 0.86 | CSNK1D (0.53) | PIK3CARIPK1CSNK1DCSNK1ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | claimed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | claimed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | claimed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | claimed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | claimed |
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | PIK3CA 475/4885RIPK1 4566/4885CSNK1D 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.